Product Name | Flumazenil |
Description |
Benzodiazepine antagonist |
Purity | >98% (HPLC); NMR (conforms) |
CAS No. | 78755-81-4 |
Molecular Formula | C15H14FN3O3 |
Molecular Weight | 303.3 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Antagonist |
Solubility | May be dissolved in DMSO (8 mg/ml) |
Source | Synthetic |
Appearance | White powder |
SMILES | CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C |
InChI | InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3 |
InChIKey | OFBIFZUFASYYRE-UHFFFAOYSA-N |
Safety Phrases |
Classification: Caution- Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection S24/25- Avoid contact with skin and eyes |
Cite This Product | Flumazenil (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-622) |
Alternative Names | 8-Fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid, ethyl ester; Ro 1722; Ro 15-1788 |
Research Areas | GABA Receptors, Neuroscience, Neurotransmission, Neurotransmitter Receptors |
PubChem ID | 3373 |
Scientific Background | A benzodiazepine antagonist1, panspecific for 1,, or5-containing GABAA receptors2. Reduces withdrawal sequelae in benzodiazepine dependence3. Reverses the toxic effects, including coma and respiratory depression of zolpidem intoxication4 and gabapentin-induced coma5. |
References |
1. Möhler H., et al. (1981) J. Neurochem. 37:714. 2. Doble A., (1999) J. Psychopharmacol. 13(4 Suppl 1):S11. 3. Hood SD., et al. (2014) Br. J. Clin. Pharmacol. 77:285. 4. Lheureux P., et al.(1990) Hum. Exp. Toxicol. 9:105. 5. Masciullo M., et al. (2021) J. Med. Case Rep. 15:242. |
Reviews
There are no reviews yet.